UCB MOG001 COSMog
STUDY AND PROTOCOL
MOG001
STUDY DETAILS
A randomized, double-blind, placebo controlled, multicenter, phase3, pivotal study with an open-label extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD)
FURTHER INFORMATION
ClinicalTrials.gov Identifier: NCT05063162